Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06057402 · View on ClinicalTrials.gov ↗
Study Summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Conditions Studied
Interventions
- DRUG Elranatamab
Study Locations (20)
Colorado
- UCHealth Poudre Valley Hospital — Fort Collins
- UCHealth Harmony — Fort Collins
- UCHealth Greeley Hospital — Greeley
- Longs Peak Hospital — Longmont
- UCHealth Longs Peak Medical Center — Longmont
- UCHealth - Medical Center of the Rockies — Loveland
Florida
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables
- University of Miami Hospital and Clinics Deerfield Beach — Deerfield Beach
- Sylvester Comprehensive Cancer Center — Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building — Miami
- University of Miami Hospital and Clinics — Miami
Victoria
- Epworth Freemasons — Melbourne
- Epworth Hospital — Richmond
- Slade Pharmacy — Richmond
Michigan
- University of Michigan — Ann Arbor
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit
Alberta
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary
- Cross Cancer Institute — Edmonton
Texas
- St. David's South Austin Medical Center — Austin
Quebec
- McGill University Health Centre — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2032-02-22 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06057402
The ClinicalTrials.gov registry entry for NCT06057402 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention — of which Elranatamab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06057402 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Colorado, Florida, Victoria. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06057402 about?
NCT06057402 is a clinical study titled "Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)". This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
What is the current status of trial NCT06057402?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2023-10-03. Estimated completion is 2032-02-22.
What conditions does trial NCT06057402 study?
This clinical trial studies the following conditions: Multiple Myeloma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06057402?
The interventions under investigation include: Elranatamab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06057402?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06057402 being conducted?
This trial has 20 study locations across Colorado, Florida, Michigan, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.